{"id":9447,"date":"2025-04-18T01:32:00","date_gmt":"2025-04-18T01:32:00","guid":{"rendered":"https:\/\/afcra-smo.org\/?p=9447"},"modified":"2026-06-04T14:50:36","modified_gmt":"2026-06-04T14:50:36","slug":"lenacapavir-prevention-vih-afrique-2025","status":"publish","type":"post","link":"https:\/\/afcra-smo.org\/en\/lenacapavir-prevention-vih-afrique-2025\/","title":{"rendered":"Lenacapavir: a major breakthrough in HIV prevention in Africa"},"content":{"rendered":"
\n\n
\n \"L\u00e9nacapavir\n <\/figure>\n\n

\n HIV remains one of the most pressing public health challenges in Africa, particularly affecting the young women<\/strong>. A major scientific breakthrough could be a game changer: the development of a new preventative drug administered only \n twice a year<\/strong>.\n <\/p>\n\n

The limitations of current prevention<\/h2>\n\n

\n Until now, HIV prevention has relied primarily on the oral pre-exposure prophylaxis (PrEP)<\/strong>, requiring daily administration. This adherence requirement significantly limits its effectiveness in practice. Furthermore, in the vast majority of people on antiretroviral therapy, stopping treatment leads to... \n rapid rebound of viral load<\/strong>, accompanied by a weakening of the immune system linked to a decrease in CD4+ T lymphocytes.\n <\/p>\n\n

Lenacapavir: a revolution in two injections per year<\/h2>\n\n

\n In a recent clinical study conducted in South Africa and Uganda<\/strong>, a new preventive antiretroviral \u2014 the lenacapavir<\/strong> \u2014 has demonstrated particularly promising results. Administered in the form of two injections per year<\/strong>, It prevented any HIV infection among the study participants.\n <\/p>\n\n